156 related articles for article (PubMed ID: 23321318)
1. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Pol S; Aerssens J; Zeuzem S; Andreone P; Lawitz EJ; Roberts S; Younossi Z; Foster GR; Focaccia R; Horban A; Pockros PJ; Van Heeswijk RP; De Meyer S; Luo D; Botfield M; Beumont M; Picchio G
J Hepatol; 2013 May; 58(5):883-9. PubMed ID: 23321318
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
3. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA
PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189
[TBL] [Abstract][Full Text] [Related]
4. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
5. Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
Foster GR; Zeuzem S; Andreone P; Pol S; Lawitz EJ; Diago M; Roberts S; Pockros PJ; Younossi Z; Lonjon-Domanec I; De Meyer S; Luo D; George S; Beumont M; Picchio G
J Hepatol; 2013 Mar; 58(3):488-94. PubMed ID: 23183521
[TBL] [Abstract][Full Text] [Related]
6. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
7. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
[TBL] [Abstract][Full Text] [Related]
9. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
10. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.
Nakagawa A; Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Arai T; Hashimoto S; Matsushita Y; Fukuda T; Nakatsuka K; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1329-34. PubMed ID: 25357216
[TBL] [Abstract][Full Text] [Related]
11. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
12. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
[TBL] [Abstract][Full Text] [Related]
13. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
[TBL] [Abstract][Full Text] [Related]
14. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Pockros PJ; Jensen D; Tsai N; Taylor R; Ramji A; Cooper C; Dickson R; Tice A; Kulkarni R; Vierling JM; Lou Munson M; Chen YC; Najera I; Thommes J;
Hepatology; 2013 Aug; 58(2):514-23. PubMed ID: 23359491
[TBL] [Abstract][Full Text] [Related]
15. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
18. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
Bota S; Sporea I; Şirli R; Neghină AM; Popescu A; Străin M
Clin Drug Investig; 2013 May; 33(5):325-31. PubMed ID: 23532802
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
